Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?

To: John F Beule who wrote (1051)	2/2/1999 1:01:00 PM
From: Anthony Wong	Respond to of 2539

John, it's ironic that the study was funded by Searle. This is old news, but the Washington Times and now the Philadelphia Enquirer have picked up the story. If this is a so-so drug, no one would be interested.

To: John F Beule who wrote (1051)	2/2/1999 2:41:00 PM
From: Dan Spillane	Read Replies (1) \| Respond to of 2539

John, that "news" has been discussed for weeks and was mentioned on TV recently...go back in either this folder or the Yahoo folder. The only reason this is being picked up is because of the success of Celebrex...if you sell Motrin you're not happy that 6% of the market went to a new drug in only two weeks! I also understand the guy who did the study only took on a "negative spin" once he left UPenn...hmmmmmmm. And the study is only a theory which has been counter-proven by clinical trials over many people.